A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT ID: NCT05305547

Last Updated: 2025-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2093 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-03

Study Completion Date

2024-05-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

S-217622

S-217622 will be administered orally for 5 days.

Group Type EXPERIMENTAL

S-217622

Intervention Type DRUG

Administered as a round tablet.

Placebo

Placebo matching to S-217622 will be administered orally for 5 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered as a round tablet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

S-217622

Administered as a round tablet.

Intervention Type DRUG

Placebo

Administered as a round tablet.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documentation of laboratory-confirmed active SARS-CoV-2 infection, as determined by a nucleic acid (for example, reverse-transcriptase PCR) or antigen test from any respiratory tract specimen (for example, oropharyngeal, NP or nasal swab, or saliva) collected ≤72 hours (3 days) prior to randomization.
* Participants are expected to begin study intervention ≤3 days from self-reported date of onset of any of the COVID-19-related symptoms from the following list:
* Cough
* Shortness of breath or difficulty breathing
* Feeling feverish
* Chills
* Fatigue
* Body pain or muscle pain or aches
* Diarrhea
* Nausea
* Vomiting
* Headache
* Sore throat
* Nasal obstruction or congestion
* Nasal discharge
* Loss of taste
* Loss of smell
* One or more of the following signs/symptoms present within 24 hours prior to randomization:
* Cough
* Shortness of breath or difficulty breathing
* Feeling feverish
* Chills
* Fatigue
* Body pain or muscle pain or aches
* Diarrhea
* Nausea
* Vomiting
* Headache
* Sore throat
* Nasal obstruction or congestion
* Nasal discharge
* Participants at higher risk of progression to severe COVID-19 are defined as follows:
* Age ≥65 years
* Age ≥18 with 1 of the following:
* Obesity (body mass index \[BMI\] ≥30 kilograms per square meter \[kg/m\^2\]). Note: BMI is rounded to the nearest whole number, for example 29.5 kg/m\^2 is rounded to 30 kg/m\^2.
* Diabetes mellitus
* Hypertension requiring daily prescribed therapy
* Cardiovascular disease (requiring daily prescribed therapy or congenital heart disease)
* Chronic lung disease (for example, chronic obstructive pulmonary disease, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension) requiring daily prescribed therapy
* Chronic kidney disease, defined as known current kidney impairment with a creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) \<60 milliliters (mL)/minute (min)/1.73 square meter (m\^2) within the past 12 months prior to randomization, as long as the participant does not have known CrCl \<30 mL/min by Cockcroft-Gault or require dialysis
* Down syndrome
* Sickle cell disease
* One of the following immunocompromising conditions or immunosuppressive treatments:
* Receiving chemotherapy or other therapies for cancer
* Hematologic malignancy (active or in remission)
* History of a hematopoietic stem cell or a solid organ transplant
* Human immunodeficiency virus infection: not on antiretroviral therapy or with cluster of differentiation 4+ cell count \<200 cells per cubic millimeter
* Combined primary immunodeficiency disorder
* Taking immunosuppressive medications (for example, drugs to suppress rejection of transplanted organs or to treat rheumatologic and gastrointestinal conditions, such as anti-tumor necrosis factor agents, mycophenolate, and rituximab).

Note: Current use of some corticosteroids is exclusionary, due to concern for possible drug-drug interaction (DDI) with S-217622.

Exclusion Criteria

* History of hospitalization for the current SARS-CoV-2 infection (that is, prior hospitalization for a prior episode of SARS-CoV-2 infection is allowable)
* For the current SARS-CoV-2 infection, any positive SARS-CoV-2 molecular (nucleic acid) or antigen test from any respiratory tract specimen (for example, oropharyngeal, NP, or nasal swab, or saliva) collected ˃72 hours (3 days) prior to randomization. Participants with reinfection, defined as prior SARS-CoV-2 infection that began \>90 days prior to the current onset of symptoms with interval resolution of symptoms are eligible as long as the current infection has not been present for more than 3 days prior to randomization.
* Current need for hospitalization or immediate medical attention in the opinion of the investigator
* Current use of any medications prohibited with the study intervention. Individuals who have used Paxlovid or any other oral, inhaled, or injectable medication intended to treat the current SARS-CoV-2 infection before randomization are excluded. After randomization, locally available SARS-CoV-2 treatment (including but not limited to molnupiravir, mAbs, outpatient IV remdesivir, convalescent plasma, inhaled budesonide, favipiravir, and fluvoxamine) will be permitted, as long as there are no concerns for DDIs.

Note: Paxlovid use for a prior episode of COVID-19 is permitted.

* Receipt of any investigational treatments for the current episode of SARS-CoV-2 at any time prior to randomization is exclusionary. Note: This does not include drugs approved for other uses and taken for those indications or COVID-19 vaccines. Note: Use of locally authorized or approved therapies to prevent COVID-19, such as mAbs given solely to prevent COVID-19, are not exclusionary.
* Any co-morbidity requiring surgery within 7 days prior to randomization or that is considered life threatening in the opinion of the investigator within 28 days prior to randomization
* Known allergy/sensitivity or any hypersensitivity to components of S-217622 or placebo for S-217622
* Known (within 12 months prior to randomization) renal impairment defined as CrCl \<30 mL/min by Cockcroft-Gault or requiring dialysis
* Known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy)
* Participants who have used any of the following drugs within 14 days prior to randomization:
* Strong cytochrome P453A inducer
* Products containing St. John's Wort
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Shionogi

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lakeview Clinical Research

Guntersville, Alabama, United States

Site Status

Voyage Medical Services

Tempe, Arizona, United States

Site Status

Novak Clinical Research

Tucson, Arizona, United States

Site Status

Hope Clinical Research

Canoga Park, California, United States

Site Status

Carbon Health

Culver City, California, United States

Site Status

NICR

Garden Grove, California, United States

Site Status

Ark Clinical Research (PARENT)

Long Beach, California, United States

Site Status

UCSD Antiviral Research Center

San Diego, California, United States

Site Status

University of California San Francisco (PARENT)

San Francisco, California, United States

Site Status

Clinical Trials Management Services, 223 E. Thousand Oaks Blvd.

Thousand Oaks, California, United States

Site Status

Lundquist Institute for BMI, UCLA Medical Center

Torrance, California, United States

Site Status

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Site Status

Whitman-Walker Health

Washington D.C., District of Columbia, United States

Site Status

University of Florida Clinical & Translational Science Institute

Gainesville, Florida, United States

Site Status

Universal Medical and Research Center

Miami, Florida, United States

Site Status

CCR Medical Center, Suite 201

Miami, Florida, United States

Site Status

Miami Clinical Research

Miami, Florida, United States

Site Status

Vista Health Research, LLC

Miami, Florida, United States

Site Status

Quantum Clinical Trials, 333 Arthur Godfrey Road, Suite 202, suite 208

Miami Beach, Florida, United States

Site Status

Quality Research of South Florida

Miami Lakes, Florida, United States

Site Status

Accel Research Sites Network, Ormond Clinical Research Unit, 77 West Granada Boulevard

Ormond Beach, Florida, United States

Site Status

Clinical Research Center of Florida, 550 SW 3rd St.,, Suite #305

Pompano Beach, Florida, United States

Site Status

Invictus Clinical Research Group, LLC

Pompano Beach, Florida, United States

Site Status

Santos Research Center, CORP

Tampa, Florida, United States

Site Status

Masters of Clinical Research

Augusta, Georgia, United States

Site Status

Leavitt Clinical Research

Idaho Falls, Idaho, United States

Site Status

Research Network America

Berwyn, Illinois, United States

Site Status

Rush University Infectious Diseases

Chicago, Illinois, United States

Site Status

Tandem Clinical Research

Marrero, Louisiana, United States

Site Status

The Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status

Infusion Associates

Grand Rapids, Michigan, United States

Site Status

Revival Research Institute LLC

Troy, Michigan, United States

Site Status

Las Vegas Medical Research

Las Vegas, Nevada, United States

Site Status

AB Clinical Trials

Las Vegas, Nevada, United States

Site Status

Renal Medicine Associates

Albuquerque, New Mexico, United States

Site Status

Columbia University Irving Medical Center Division of Infectious Diseases

New York, New York, United States

Site Status

NY Blood Center Project ACHIEVE

New York, New York, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

Lapis Clinical Research - North State

Denver, North Carolina, United States

Site Status

Burke Primary Care

Morgantown, North Carolina, United States

Site Status

Progressive Medicine of the Triad, LLC

Winston-Salem, North Carolina, United States

Site Status

Ohio State University College of Medicine

Columbus, Ohio, United States

Site Status

Infectious Disease Clinical Trials Unit-University of Pennsylvania Health System

Philadelphia, Pennsylvania, United States

Site Status

UPMC Eye Center - Eye and Ear Institute

Pittsburgh, Pennsylvania, United States

Site Status

Vanderbilt Health-One Hundred Oaks

Nashville, Tennessee, United States

Site Status

Central Texas Medical Research

Austin, Texas, United States

Site Status

Care United Research, 375 North FM 548, suite 100

Forney, Texas, United States

Site Status

Valley Institute of Research

Fort Worth, Texas, United States

Site Status

Trio Clinical Trials, LLC.

Houston, Texas, United States

Site Status

Accurate Clinical Management, LLC

Houston, Texas, United States

Site Status

Sun Research Institute, LLC

San Antonio, Texas, United States

Site Status

Progressive Clinical Research

Bountiful, Utah, United States

Site Status

Clinical Research Partners LLC

Richmond, Virginia, United States

Site Status

CINME Centro Investigaciones Metabolicas, Pres. Jose Evaristo Uriburu 754, Piso 3 dpto 12

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Sanatorio De La Trinidad, Mitre Bartolome Mitre

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Hospital Italiano sede Central, Tte. Gral. Juan Domingo Perón 4190

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Centro Privado de Medicina Familiar, Mindout Research

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Centro De Investigaciones

Mar del Plata, Buenos Aires, Argentina

Site Status

DIM Clínica Privada, Belgrano 136 - 5to piso

Ramos Mejía, Buenos Aires, Argentina

Site Status

Hospital General Agudos Dr. J.M., Grl Justo José de Urquiza 609 2do piso, Pabellón Clínica Médica, Enf. Emergentes

Ramos Mejía, Buenos Aires, Argentina

Site Status

Clínicas Zárate, F. Andrade 332

Zárate, Buenos Aires, Argentina

Site Status

Sanatorio Privado ,Duarte Quiros

Quiros, Córdoba Province, Argentina

Site Status

Instituto Médico de la, Fundación Estudios Clínicos, Italia 428, Rosario

Rosario, Sante Fe, Argentina

Site Status

Clinica Mayo UMCB

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Clínica Olivos

Buenos Aires, , Argentina

Site Status

Sanatorio Allende, Av.

Córdoba, , Argentina

Site Status

CER San Juan,

San Juan, , Argentina

Site Status

Mendoza 2612, Rosario

Santa Fe, , Argentina

Site Status

SENAI CIMATEC Clinical Trial Research Center

Salvador, Estado de Bahia, Brazil

Site Status

AMB3 Servicos Medicos Ltda Rua Campinas

Cuiabá, Mato Grosso, Brazil

Site Status

Faculdade de Medicina da univ., Federal, Av Alfredo Balena, 190, 1° andar - sala 161

Belo Horizonte, Minas Gerais, Brazil

Site Status

Hosp Nossa Senhora das Gracas, Rue Alcides Munhoz

Curitiba, Paraná, Brazil

Site Status

Instituto Atena de Psequisa Clinica Ltds, Av Marechal Floriano Peixoto

Natal, Rio Grande do Norte, Brazil

Site Status

Thainá Garbino dos Santos, Avenida Protásio Alves 211, Bloco C

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

IPARGS, Rua Antonio Joaquim Mesquita

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Fundação Pio XII - Hospital de Amor de, Barretos; Rua Antenor Duarte Villela

Baretos, São Paulo, Brazil

Site Status

Unid Pesquisa Clínica Facultad Medicina, de Botucatu UNESP, Rua Prof. Dr. Armando,Alves s/n, Distrito de rubião Junior

Botucatu, São Paulo, Brazil

Site Status

Hospital Universario Sao Francisco, na Providencia de Deus-Av. Sao Francisco de Assis

Bragança Paulista, São Paulo, Brazil

Site Status

Instituto de Pesquisa Clinica de Campinas IPECC Tua Oswaldo

Campinas, São Paulo, Brazil

Site Status

Cecip Jau

Jaú, São Paulo, Brazil

Site Status

Pesquisare Saude

Santo André, São Paulo, Brazil

Site Status

CEMEC

São Bernardo do Campo, São Paulo, Brazil

Site Status

Esperanca Clinica De Pesquisas

São Paulo, São Paulo, Brazil

Site Status

Instituto de Molestast Cardiovasculares

Tatuí, São Paulo, Brazil

Site Status

Hospital da Puc Campinas, Centro de Pesquisa Sao Lucas

Campinas, , Brazil

Site Status

IBPClin, Rua da Gloria

Rio de Janeiro, , Brazil

Site Status

INI/Fiocruz

Rio de Janeiro, , Brazil

Site Status

Lóbus Cntr. de Pesquisa Cl.

Volta Redonda, , Brazil

Site Status

Programa de estudios y control de, enfermedades tropicales PECET, Carrera 53 N°61-30 Torre 2, Lab. 632

Medellín, Antioquia, Colombia

Site Status

Centro de Investigación Medico, Asistencia - CIMEDICAL S.A.S, Cra 49C # 82-120

Barranquilla, Atlántico, Colombia

Site Status

Corazon IPS S.A.S, Carrera 49 No 74 - 158

Barranquilla, Atlántico, Colombia

Site Status

IPS CENTRO CIENTIFICO ASISTENCIAL S.A.S, Cra 45 #85-49

Barranquilla, Atlántico, Colombia

Site Status

Centro de investigación en Reumatología, y Especialidades Medicas S.A.S, CIREEM S.A.S.-Cra. 12#97-32

Bogotá, Bogota D.C., Colombia

Site Status

Fundación Centro Excelencia en Enferm., Crónicas No Transmisibles-FUNCENTRA, CRA 3 N°21 44 B,

Chuchurubi Monteria, Departamento de Córdoba, Colombia

Site Status

TyC Inversiones SAS Grupsalud 33-6 IPS, Avenida Libertador # 30-360, Barrio San Pedro Alejandrino

Santa Marta, Magdalena Department, Colombia

Site Status

Fundación Cardiomet Cequin,, Street 18 North # 14-25,

Armenia, Quindío Department, Colombia

Site Status

BlueCare Salud SAS

Bogotá, , Colombia

Site Status

Navrongo Health Research Cntr

Upper East, Navrongo, Ghana

Site Status

Kintampo Health Research Cntr

Kintampo, , Ghana

Site Status

Kumasi Centre for Research, South End Asuogya Road, Kwame Nkrumah University

Kumasi, , Ghana

Site Status

St. Theresa's Hospital

Hyderabad, Andhra Pradesh, India

Site Status

DEC-Health Care Hospital

Nellore, Andhra Pradesh, India

Site Status

Vijaya Super Speciality Hospital

Nellore, Andhra Pradesh, India

Site Status

King George Hospital

Visakhapatnam, Andhra Pradesh, India

Site Status

Sangini Hospital 1st Flr & 7th flr

Ahmedabad, Gujarat, India

Site Status

Aman Hospital and Research Center

Vadodara, Gujarat, India

Site Status

Rhythm Heart Institute - A Unit Of SLPL

Vadodara, Gujarat, India

Site Status

ESIC Medical College & Hospital

Faridabad, Haryana, India

Site Status

Sarvodaya Hospital and Research Centre

Faridabad, Haryana, India

Site Status

BGS Global institute of Medical Sciences

Bangalore, Karnataka, India

Site Status

KLEs Dr. Prabhakar Kore Hospital & MRC Belagavi

Belagavi, Karnataka, India

Site Status

Sri Lakshmi Super Speciality Hospital

Bengaluru, Karnataka, India

Site Status

Shettys Hospital

Bengaluru, Karnataka, India

Site Status

Sri Venkateshwara Hospitals, SKY HEIGHTS, Site#1/2, Sarjapura-Attibele, Main rd, Indelebele Village

Bengaluru, Karnataka, India

Site Status

Yenepoya Med College Hosp, EMD Building, 5th fl., University Rd, Deralakatte

Mangalore, Karnataka, India

Site Status

BAJ RR Hosp and Res Cntr

Dombivali, Maharashtra, India

Site Status

Chopda Medicare & Research Centre Pvt. Ltd

Nashik, Maharashtra, India

Site Status

Lifepoint Multispecialty Hosp.

Pune, Maharashtra, India

Site Status

Sir Ganga Ram Hospital

New Delhi, National Capital Territory of Delhi, India

Site Status

Aakash Healthcare Private Limited

Dwārka, New Delhi, India

Site Status

JNUIMSRC

Jaipur, Rajasthan, India

Site Status

Tagore Hospital & Research Institute

Jaipur, Rajasthan, India

Site Status

Voluntary Health Services Infectious Diseases Medical CEN CART Clinical Research Site

Chennai, Tamil Nadu, India

Site Status

Department of Medicine

Kanpur, Uttar Pradesh, India

Site Status

HB Specialty Hosp. & Res Inst.

Rudrapur, Uttarakhand, India

Site Status

Calcutta School of Tropical Medicine

Kolkata, West Bengal, India

Site Status

Kohokai Takagi Hospital

Okawa-shi, Fukuuoka-Ken, Japan

Site Status

Tsuchiura Beryl Clinic

Tsuchiura-shi, Ibaraki, Japan

Site Status

University of Tsukuba Hospital

Tsuchiura-shi, Ibaraki, Japan

Site Status

Tashiro Endocrinology Clinic

Tsukuba, Ibaraki, Japan

Site Status

Kodaira Hospital

Toda-shi, Saitama, Japan

Site Status

Moi University Clin Res Centre, 2nd Fl, Chandaria Chronic, Disease and Cancer Centre

Eldoret, , Kenya

Site Status

KEMRI CGHR HIVR Site

Kisumu, , Kenya

Site Status

Johns Hopkins Research Project, Queen Elizabeth Central Hospital

Chipatala Avenue, Blantyre, Malawi

Site Status

UNC Project, Private Bag A-104

Lilongwe, , Malawi

Site Status

Mangochi PHNG Study Site, Kamuzu University of Health Sciences, Private Bag 360, Room 805

Mangochi, , Malawi

Site Status

CAIMED Investigación en Salud, S.A. de C.V., Manzanillo #100. Piso 2. Roma Sur

Cuauhtémoc, Cdmx, C.P, Mexico

Site Status

Instituto Veracruzano, en Investigación Clínica S.C., Sabino s/n, Colonia Reserva Tarimoya ll

Veracruz, CP, Mexico

Site Status

Avenida Universidad 1001, Edificio 19, planta baja, colonia Chamilpa

Cuernavaca, Morelos, Mexico

Site Status

Oaxaca Site Management Organization S.C., Humboldt 302, Col. Centro.

Oaxaca City, Oaxaca, Mexico

Site Status

Centro Inv. y Avances Med Especializados, (CIAME) Av. Kabah, Lote 38, 39 y 41., Manzana 4, supermanzana 44. Col., Alborada, Benito Juárez

Cancún, Quintana Roo, Mexico

Site Status

FAICIC S. DE R.L. DE C.V., Av. 16 de Septiembre 1165

Ricardo Flores Magón, Veracruz, Mexico

Site Status

Hospital Cardiológica Aguascalientes, Ecuador 200 Fracc Las Américas

Aguascalientes, , Mexico

Site Status

Centro de Inv. Médica Aguascalientes, (CIMA) Av. Independencia 2130, Int. A. Trojes de Alonso

Aguascalientes, , Mexico

Site Status

Indus Hospital and Health Network

Korangi, Karachi, Pakistan

Site Status

Rehman Medical Institute Clinical Trial Unit

Hayatabad, Peshawar, Pakistan

Site Status

Central Park Teaching Hospital

Lahore, Punjab Province, Pakistan

Site Status

National Hospital & Medical Center

Lahore, Punjab Province, Pakistan

Site Status

Akram Medical Complex

Lahore, Punjab Province, Pakistan

Site Status

The Aga Khan University

Karachi, Sindh, Pakistan

Site Status

Shifa International Hospital, 4 Pitras Bukhari Rd, H-8/4, H-8

Islamabad, , Pakistan

Site Status

Dow Univ of Health Sciences Ojha Campus

Karachi, , Pakistan

Site Status

Sindh Infectious Disease Hospital and research Centre

Karachi, , Pakistan

Site Status

Maroof International Hospital

Peshawar, , Pakistan

Site Status

Centro de Investigación

San Isidro, Lima region, Peru

Site Status

Asoc. Civil Selva Amazonica

Iquitos, Loreto, Peru

Site Status

Centro de Inv. Tecnológicas Biomédicas y Medioambientales

Lima, , Peru

Site Status

Asoc. Civil Impacta Salud y Educación - Sede San Miguel

Lima, , Peru

Site Status

Patricia Ortiz Bazan

Lima Cercado, , Peru

Site Status

Mary Mediatrix Medical Cntr

Lipa, Batangas, Philippines

Site Status

Mary Johnston Hospital, 1221 Juan Nolasco Street

Tondo, Manila, Philippines

Site Status

Iloilo Doctors' Hospital, Room 706, New Condoclinics Bldg, West Ave

Lloilo, Molo, Philippines

Site Status

The Medical City Clark, #100Eatwick, Gatewick, Global Gateway Logistics City, Industrial Estate 5, Clark Freeport Zone

Mabalacat, Pampanga, Philippines

Site Status

Ilocos Training and Regional Medical Center

La Union, San Fernando, Philippines

Site Status

Green City Medical Center

Pampanga, San Fernando, Philippines

Site Status

Health Cube Medical Clinics, High Pointe Medical Hub, 241 Shaw Blvd

Mandaluyong, , Philippines

Site Status

Lung Center of the Philippines

Quezon City, , Philippines

Site Status

Ostrowieckie Centrum Medyczne

Ostrowiec Świętokrzyski, , Poland

Site Status

Medicome sp. z o.o.

Oświęcim, , Poland

Site Status

Centrum Medyczne "Medyk"

Rzeszów, , Poland

Site Status

Clinmedica Research sp. z o.o.

Skierniewice, , Poland

Site Status

Centrum Badań Klinicznych

Wroclaw, , Poland

Site Status

JOSHA Research

Bloemfontein, Free State, South Africa

Site Status

Newton Clinical Research Centre

Johanesburg, Gauteng, South Africa

Site Status

Worthwhile Clinical Trials

Johannesburg, Gauteng, South Africa

Site Status

(PHRU), New Nurses Home 9th floor Chris

Johannesburg, Gauteng, South Africa

Site Status

CHRU, Themba Lethu Clinic

Johannesburg, Gauteng, South Africa

Site Status

Ubuntu Clinical Research

Krugersdorp, Gauteng, South Africa

Site Status

Ubuntu Clinical Research

Lenasia, Gauteng, South Africa

Site Status

T/A Midrand Medical Centre, Shop #1, Health Emporium

Midrand, Gauteng, South Africa

Site Status

Global Clinical Trials

Pretoria, Gauteng, South Africa

Site Status

Right to Care Research Esizayo, Right Clinic Esizayo

Randburg, Gauteng, South Africa

Site Status

Limpopo Clin Res Initiative Tamboti Medical Centre

Thabazimbi, Limpopo, South Africa

Site Status

The Arum Institute NPC Rustenburg CRS

Rustenburg, North West, South Africa

Site Status

Task Eden Research Centre

George, Western Cape, South Africa

Site Status

Be Part Research PTY (LTD)

Paarl, Western Cape, South Africa

Site Status

Roodepoort Medicross Clinical Research Centre

Roodepoort, , South Africa

Site Status

Siriraj Hospital

Bangkok Noi, Bangkok, Thailand

Site Status

Thai Red Cross AIDS Research Centre

Pathum Wan, Bangkok, Thailand

Site Status

Srinagarind Hospital

Mueang Khon Kaen District, Changwat Khon Kaen, Thailand

Site Status

Research Institute for Health Sciences

Mueang Chiang Mai District, Chiang Mai, Thailand

Site Status

Joint Clinical Research Centre

Kampala, , Uganda

Site Status

Infectious Diseases Institute (IDI), Mulago Hill Road

Kampala, , Uganda

Site Status

Joint Clinical Research Centre

Kampala, , Uganda

Site Status

SICRA, Lira Regional Referral, Plot 21-41 Ngetta Road P.O. Box 330062

Lira, , Uganda

Site Status

IDRC Clinic, Tororo General Hospital, P.O. Box 2, Station Rd

Tororo, , Uganda

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Brazil Colombia Ghana India Japan Kenya Malawi Mexico Pakistan Peru Philippines Poland South Africa Thailand Uganda

References

Explore related publications, articles, or registry entries linked to this study.

Luetkemeyer AF, Chew KW, Lacey S, Hughes MD, Harrison LJ, Daar ES, Eron J, Fletcher CV, Greninger AL, Hessinger D, Li JZ, Mailhot D, Wohl D, Chayakulkeeree M, Mendoza JLA, Elistratova P, Makinde O, Morgan G, Portsmouth S, Uehara T, Smith D, Currier JS. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. Clin Infect Dis. 2025 Jul 18;80(6):1235-1244. doi: 10.1093/cid/ciaf029.

Reference Type DERIVED
PMID: 39960062 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACTIV-2d/A5407

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Paxlovid for Treatment of Long Covid
NCT05576662 COMPLETED PHASE2